Encompass Health Beats EPS, Raises FY2026 Guidance; Stock Edges Higher in After‑Hours Trade

Earnings Snapshot

- GAAP EPS: $1.77 vs. $1.51 estimate (beat by $0.26)

- Non‑GAAP EPS: $1.60 vs. $1.51 estimate (beat by $0.09)

- Revenue: $1,587 million vs. $1,570 million estimate (miss by $1.6 million, +9.0% YoY)

- Adjusted EBITDA: $348.8 million, up 11.2% YoY

- Discharges: 67,763, a 4.3% increase YoY, with same‑store discharge growth of 1.6%

The earnings beat was driven by stronger-than‑expected patient volume and higher net patient revenue per discharge ($22,633, up 3.7% YoY). The slight revenue miss reflects a modest shortfall against consensus, but the 9% YoY growth kept the top line comfortably above the prior year.

Guidance & Outlook

During the earnings call, CEO Mark Tarr highlighted the company’s aggressive capacity expansion: a new 49‑bed hospital in Irmo, South Carolina, and 44 additional beds across existing sites. The firm now expects to open eight hospitals in 2026, adding 389 beds, and to increase existing capacity by roughly 175 beds.

The updated FY 2026 guidance, confirmed in the 8‑K, is:

- Net operating revenue: $6.375 billion to $6.470 billion (previously $6.365‑$6.465 billion)

- Adjusted EBITDA: $1.350 billion to $1.380 billion (unchanged lower bound, raised upper bound)

- Adjusted EPS: $5.89 to $6.11 (previously $5.81‑$6.10)

MarketBeat’s instant‑alert note reported that the new EPS range of $5.89‑$6.11 sits slightly above the consensus estimate of $5.92, reinforcing the bullish tone.

Conference Call Highlights

- Capacity build‑out: The new Irmo hospital and additional beds are expected to lift discharge volumes by an estimated 5%‑6% in FY 2026.

- Operating efficiency: Adjusted EBITDA margin expanded to 11.2% YoY, driven by higher patient revenue per discharge and disciplined cost management.

- Cash flow: Operating cash flow rose 8.5% YoY to $313.1 million, though adjusted free cash flow slipped 12.9% to $193.8 million, reflecting higher capex for the new facilities.

- Outlook on reimbursement: Management reiterated confidence that upcoming Medicare rate adjustments (RCD and TEAM) will sustain margin expansion.

Market Reaction

The after‑hours market gave EHC a modest lift, trading at $100.06, up 0.06% from the prior close of $100.00. The modest price move reflects a balancing act: investors rewarded the EPS beat and raised guidance, but the slight revenue miss and a dip in adjusted free cash flow kept enthusiasm tempered.

Analyst Commentary

- Price target: Yahoo Finance’s analyst consensus lifted the median price target to $122.71, up from $118.30 a month ago, citing the stronger earnings profile and the aggressive hospital expansion plan.

- Buy rating: The majority of Wall Street analysts maintain a “Buy” stance, emphasizing the company’s market‑leading inpatient rehab footprint and the upside from new capacity.

- Risks: Analysts flagged potential headwinds from labor cost inflation and uncertain Medicare policy changes, but agreed that the current guidance leaves ample room for upside.

What’s Next?

EHC will host its earnings webcast on May 1 at 10:00 a.m. ET. Investors will be watching for updates on the Irmo hospital construction timeline, the impact of Medicare rate changes, and any revisions to free‑cash‑flow expectations as capex ramps.

---

The article reflects data from the company’s 8‑K filing and market reaction as of 6:19 PM ET on April 30, 2026.